Biotech Values

[SimpleTruths]

If the trial arms would appropriately balanced, it'd be at fools errand to run the trial to ten years looking for that comparison if it's already shown up strongly at three.

However, the problem I see with the data released to date is that there's no data on the ITT analysis, measured from randomization. My supposition is that the company missed on stat sig for that population (.06?) but managed .047 when measuring from vaccination as the graphic represents.

That doesn't mean the vaccine isn't helping, but it does mean they have almost no chance of getting approval from this FDA.

ST